Rankings
Publications
Search Publications
Cited-by Search
Sources
Publishers
Scholars
Scholars
Top Cited Scholars
Organizations
About
Scilit
About Us
Advisory Board
Data Sources
Career
Support / Contact
User Guide
Publisher User
Search Function
Rankings Function
API Resource
Scilit Knowledge
Metrics
Scilit Recognitions
Publications Classification
Media
News
Blog
Login
Register
Home
Publications
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Home
Publications
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial
Authors:
AP
A. Prat
A. Prat
CF
C. Falato
C. Falato
LB
L. Pare Brunet
L. Pare Brunet
OS
O. Martinez Saez
O. Martinez Saez
JA
J.M. Cejalvo Andujar
J.M. Cejalvo Andujar
MV
M. Margeli Vila
M. Margeli Vila
PT
P. Tolosa
P. Tolosa
FB
F.J. Salvador Bofill
F.J. Salvador Bofill
JJ
J. Cruz Jurado
J. Cruz Jurado
BG
B. Gonzalez-Farre
B. Gonzalez-Farre
ET
E. Sanfeliu Torres
E. Sanfeliu Torres
EC
E.M. Ciruelos
E.M. Ciruelos
See more
Article Alert
Citation Alert
Add to Library
Cite
Download
Share
Download
Download PDF
Download
Publisher website
Google Scholar
5 May 2022
journal article
abstracts
Published by
Elsevier
in
Annals of Oncology
Vol. 33
,
S164
DOI:
10.1016/j.annonc.2022.03.279
Abstract
No abstract available
Keywords
PATRITUMAB DERUXTECAN
TRIAL SOLTI
BREAST CANCER
FINAL RESULTS
PREVIOUSLY REPORTED
DIRECTED ANTIBODY
DRUG CONJUGATE
OPPORTUNITY TRIAL
CLINICAL ACTIVITY
ANTIBODY DRUG
Cited
Cited by 10 articles
Scroll to top